+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Middle East and Africa Neurological Biomarker Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Product, Application, and End User

  • PDF Icon

    Report

  • 121 Pages
  • April 2021
  • Region: Africa, Middle East
  • The Insight Partners
  • ID: 5316749
UP TO OFF until Mar 31st 2024
The Middle East and Africa neurological biomarker market is expected to reach US$ 529.04 million by 2027 from US$ 232.80 million in 2019; it is estimated to grow at a CAGR of 11.0% from 2020 to 2027. The growth of the market is attributed to a few key driving factors such as rising prevalence of neurological diseases and growing focus on neurological biomarker research. On the other hand, concerns associated with the use of biomarkers such as the absence of pre-analytical tests are among the major factors that hinder the market growth.

Neurological biomarkers are molecules present in the cerebral spinal fluid (CSF) or blood that support the diagnosis of brain disorders and monitor disease progression. These biomarkers' primary sources are genetic mutations, metabolite levels, brain imaging, and changes in protein expression or post-translational modifications. This helps in the early detection of disease and less invasive diagnostics. It also allows faster drug development and is expected to be the effective treatment for Neurological disorders. Currently, research activities focused on biomarkers in neurodegenerative diseases are significantly increasing due to the surging incidence of Alzheimer’s and Parkinson’s diseases across Middle East and Africa. The World Alzheimer's Report 2017 estimated that 4.4 million people aged 60 years and above were living in South Africa, from which ~ 187,000 had Alzheimer’s dementia. Also, the introduction of digital biomarkers and the growing focus on neurological biomarker research are anticipated to propel the growth of the Middle East and Africa neurological biomarker market in the coming years.

The COVID-19 outbreak pandemic has adversely affected the countries in the Middle East and Africa. Patients suffering from severe health conditions such as neurological diseases have been witnessing delays in chronic disease treatment. However, many companies and research institutes are taking initiatives to accelerate research in the diagnosis, treatment, and prevention of the neurological complications that may be caused by COVID-19. Thus, the Middle East and Africa neurological biomarker market is facing challenges due to the COVID-19 outbreak.

The Middle East and Africa neurological biomarker market, based on product, is segmented into proteomics biomarker, genomics biomarker, metabolomics biomarker, imaging biomarker, and others. In 2019, the genomics biomarker segment held the largest share of the market. Moreover, the market for the same segment is expected to grow at the fastest rate during the forecast period.

Based on application, the Middle East and Africa neurological biomarker market is segmented into Alzheimer’s disease, Parkinson's disease, schizophrenia, Huntington's disease, spinal muscular atrophy, and others. The Alzheimer’s disease segment held the largest market share in 2019, and the market for the same segment is anticipated to grow at a significant rate during 2020 to 2027.

The Middle East and Africa neurological biomarker market, by end user, is segmented into pharmaceutical & biotechnology companies, clinical diagnostics, and research organizations. In 2019, the pharmaceutical & biotechnology companies segment held the largest share of the market. In addition, the market for the same segment is expected to grow at the fastest rate from 2020 to 2027.

A few of the primary and secondary sources referred to while preparing the report on the Middle East and Africa neurological biomarkers market are the African Journal of Neurological Sciences (AJNS), Bank Melli Iran (BMI), Rare Diseases South Africa (RDSA), and BMC Neurology.

Table of Contents

1. Introduction
1.1 Scope of the Study
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Middle East and Africa Neurological Biomarker Market - By Product
1.3.2 Middle East and Africa Neurological Biomarker Market - By Application
1.3.3 Middle East and Africa Neurological Biomarker Market - By End User
1.3.4 Middle East and Africa Neurological Biomarker Market - By Country
2. Neurological Biomarker Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Neurological Biomarker Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 Middle East and Africa - PEST Analysis
4.3 Expert Opinion
5. Neurological Biomarker Market - Key Market Dynamics
5.1 Key Market Drivers
5.1.1 Rising Prevalence of Neurological Diseases
5.1.2 Growing Focus on Neurological Biomarker Research
5.2 Key Market Restraints
5.2.1 Concerns Associated with Biomarkers
5.3 Key Market Opportunities
5.3.1 Increasing Awareness of Neurological Diseases Coupled with Developing Healthcare Infrastructure
5.4 Future Trends
5.4.1 The Rising Trend of Precision/Personalized Healthcare
5.5 Impact analysis
6. Neurological Biomarker Market - Middle East and Africa Analysis
6.1 Middle East and Africa Neurological Biomarker Market Revenue Forecast and Analysis
7. Neurological Biomarker Market Analysis- by Product
7.1 Overview
7.2 Neurological Biomarker Market Share, By Product, 2019 & 2027 (%)
7.3 Proteomics Biomarker
7.3.1 Overview
7.3.2 Proteomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.4 Genomics Biomarker
7.4.1 Overview
7.4.2 Genomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.5 Metabolomics Biomarker
7.5.1 Overview
7.5.2 Metabolomics Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.6 Imaging Biomarker
7.6.1 Overview
7.6.2 Imaging Biomarker Market Revenue and Forecasts to 2027 (US$ Mn)
7.7 Others
7.7.1 Overview
7.7.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)
8. Neurological Biomarker Market Analysis- by Application
8.1 Overview
8.2 Neurological Biomarker Market Share, By Application, 2019 & 2027 (%)
8.3 Alzheimer’s Disease
8.3.1 Overview
8.3.2 Alzheimer’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.4 Parkinson’s Disease
8.4.1 Overview
8.4.2 Parkinson’s Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.5 Schizophrenia
8.5.1 Overview
8.5.2 Schizophrenia Market Revenue and Forecasts to 2027 (US$ Mn)
8.6 Huntington's Disease
8.6.1 Overview
8.6.2 Huntington's Disease Market Revenue and Forecasts to 2027 (US$ Mn)
8.7 Spinal Muscular Atrophy
8.7.1 Overview
8.7.2 Spinal Muscular Atrophy Market Revenue and Forecasts to 2027 (US$ Mn)
8.8 Others
8.8.1 Overview
8.8.2 Others Market Revenue and Forecasts to 2027 (US$ Mn)
9. Neurological Biomarker Market Analysis- by End User
9.1 Overview
9.2 Neurological Biomarker Market Share, By End User, 2019 & 2027 (%)
9.3 Pharmaceutical and Biotechnology Companies
9.3.1 Overview
9.3.2 Pharmaceutical and Biotechnology Companies Market Revenue and Forecasts to 2027 (US$ Mn)
9.4 Clinical Diagnostics
9.4.1 Overview
9.4.2 Clinical Diagnostics Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Research Organizations
9.5.1 Overview
9.5.2 Research Organizations Market Revenue and Forecasts to 2027 (US$ Mn)
10. Neurological Biomarker Market Analysis and Forecasts To 2027 - Geographical Analysis
10.1 Middle East and Africa: Neurological Biomarker Market
10.1.1 Overview
10.1.2 Middle East and Africa: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.3 Middle East and Africa: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.4 Middle East and Africa: Neurological Biomarker Market, by Application, 2018-2027 (Million Units)
10.1.5 Middle East and Africa: Neurological Biomarker, Market, by End User, 2018-2027 (USD Million)
10.1.6 Middle East and Africa: Neurological Biomarker Market, by Country, 2019 & 2027 (%)
10.1.7 Saudi Arabia: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.7.1 Saudi Arabia: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.7.2 Saudi Arabia: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.7.3 Saudi Arabia: Neurological Biomarker Market, by Application, 2018-2027 (Million Units)
10.1.7.4 Saudi Arabia: Neurological Biomarker, Market, by End User, 2018-2027 (USD Million)
10.1.8 UAE: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.8.1 UAE: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.8.2 UAE: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.8.3 UAE: Neurological Biomarker Market, by Application, 2018-2027 (Million Units)
10.1.8.4 UAE: Neurological Biomarker, Market, by End User, 2018-2027 (USD Million)
10.1.9 South Africa: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.9.1 South Africa: Neurological Biomarker Market- Revenue and Forecast to 2027 (USD Million)
10.1.9.2 South Africa: Neurological Biomarker Market, by Product, 2018-2027 (USD Million)
10.1.9.3 South Africa: Neurological Biomarker Market, by Application, 2018-2027 (Million Units)
10.1.9.4 South Africa: Neurological Biomarker, Market, by End User, 2018-2027 (USD Million)
11. Impact of COVID-19 Pandemic on Middle East and Africa Neurological Biomarker Market
11.1 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
12. Company Profiles
12.1 Thermo Fisher Scientific Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Abbott
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Bio-Rad Laboratories Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 QIAGEN
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Immunarray Pvt. Ltd.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Quest Diagnostics Incorporated
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Perkin Elmer, Inc.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 MERCK KGaA
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 Glossary of Terms

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Thermo Fisher Scientific Inc.
  • Abbott
  • Bio-Rad Laboratories Inc.
  • QIAGEN
  • Immunarray Pvt. Ltd.
  • Quest Diagnostics Incorporated
  • Perkin Elmer, Inc
  • MERCK KGaA

Table Information